INDUS PHARMACEUTICALS Trademark

Trademark Overview


On Monday, March 28, 2005, a trademark application was filed for INDUS PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the INDUS PHARMACEUTICALS trademark a serial number of 78596173. The federal status of this trademark filing is REGISTERED AND RENEWED as of Thursday, October 3, 2019. This trademark is owned by IndUS Pharmaceuticals, Inc.. The INDUS PHARMACEUTICALS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of p...
indus pharmaceuticals

General Information


Serial Number78596173
Word MarkINDUS PHARMACEUTICALS
Filing DateMonday, March 28, 2005
Status800 - REGISTERED AND RENEWED
Status DateThursday, October 3, 2019
Registration Number3674488
Registration DateTuesday, August 25, 2009
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 21, 2006

Trademark Statements


Disclaimer with Predetermined Text"PHARMACEUTICALS"
Goods and Servicespharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, April 1, 2005
Primary Code042
First Use Anywhere DateFriday, March 31, 2006
First Use In Commerce DateFriday, March 31, 2006

Trademark Owner History


Party NameIndUS Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAndover, MA 01810

Party NameIndUS Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAndover, MA 01810

Party NameIndUS Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAndover, MA 01810

Trademark Events


Event DateEvent Description
Thursday, October 3, 2019NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Thursday, October 3, 2019REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Thursday, October 3, 2019REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Thursday, October 3, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, August 23, 2019TEAS SECTION 8 & 9 RECEIVED
Saturday, August 25, 2018COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, January 22, 2016TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 25, 2015NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Friday, September 25, 2015REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, September 25, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, August 21, 2015TEAS SECTION 8 & 15 RECEIVED
Tuesday, August 25, 2009REGISTERED-PRINCIPAL REGISTER
Tuesday, July 21, 2009LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, July 21, 2009ASSIGNED TO LIE
Monday, July 13, 2009ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, July 9, 2009STATEMENT OF USE PROCESSING COMPLETE
Saturday, June 13, 2009USE AMENDMENT FILED
Thursday, July 9, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 15, 2009TEAS STATEMENT OF USE RECEIVED
Wednesday, December 10, 2008EXTENSION 5 GRANTED
Wednesday, December 10, 2008EXTENSION 5 FILED
Wednesday, December 10, 2008TEAS EXTENSION RECEIVED
Thursday, June 12, 2008EXTENSION 4 GRANTED
Thursday, June 12, 2008EXTENSION 4 FILED
Thursday, June 12, 2008TEAS EXTENSION RECEIVED
Tuesday, January 8, 2008ASSIGNED TO EXAMINER
Thursday, December 13, 2007EXTENSION 3 GRANTED
Thursday, December 13, 2007EXTENSION 3 FILED
Thursday, December 13, 2007TEAS EXTENSION RECEIVED
Wednesday, June 13, 2007EXTENSION 2 GRANTED
Wednesday, June 13, 2007EXTENSION 2 FILED
Wednesday, June 13, 2007TEAS EXTENSION RECEIVED
Wednesday, December 13, 2006EXTENSION 1 GRANTED
Wednesday, December 13, 2006EXTENSION 1 FILED
Wednesday, December 13, 2006TEAS EXTENSION RECEIVED
Tuesday, June 13, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 21, 2006PUBLISHED FOR OPPOSITION
Wednesday, March 1, 2006NOTICE OF PUBLICATION
Friday, February 3, 2006LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, December 2, 2005ASSIGNED TO LIE
Tuesday, November 29, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 29, 2005EXAMINERS AMENDMENT E-MAILED
Tuesday, November 29, 2005EXAMINERS AMENDMENT -WRITTEN
Wednesday, November 23, 2005TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 17, 2005CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 17, 2005TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 25, 2005EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Tuesday, October 25, 2005EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Saturday, October 22, 2005ASSIGNED TO EXAMINER
Friday, April 1, 2005NEW APPLICATION ENTERED IN TRAM